{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:33:13Z","timestamp":1753180393299},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl J Gynecology &amp; Obste"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To identify factors affecting survival for women undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective study at Baskent University School of Medicine, Ankara, Turkey. Data were evaluated for 71 women with recurrent ovarian cancer who underwent cytoreductive surgery with R0 resection plus HIPEC between 2016 and 2019. Potential factors affecting survival (platinum sensitivity, bevacizumab administration before HIPEC, albumin and CA125 levels, presence of ascites, age, number of chemotherapy lines, and time interval between last chemotherapy and HIPEC) were evaluated. Complications of HIPEC were documented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age was 58\u00a0years, and the median follow\u2010up was 12\u00a0months. In univariate analyses, platinum sensitivity, albumin level, and time since last chemotherapy cycle affected overall survival. In multivariate Cox regression analysis, use of bevacizumab before HIPEC (hazard ratio [HR], 6.7; 95% confidence interval [CI], 1.39\u201332.3; <jats:italic>P<\/jats:italic>=0.018) and presence of ascites (HR, 5.3; 95% CI, 1.65\u201317.5; <jats:italic>P<\/jats:italic>=0.005) were independent negative prognostic factors. Seven (8.9%) women experienced grade III\u2013IV complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In recurrent ovarian cancer, HIPEC is a promising treatment with mild\u2010to\u2010moderate toxicity. However, the presence of ascites and progression under bevacizumab treatment before HIPEC seem to be negative prognostic factors; these findings will be important for patient selection.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ijgo.13410","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T07:29:35Z","timestamp":1601969375000},"page":"202-207","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic factors associated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer"],"prefix":"10.1002","volume":"152","author":[{"given":"Ali","family":"Ayhan","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology Department of Obstetrics and Gynecology Baskent University School of Medicine Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huseyin","family":"Akilli","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology Department of Obstetrics and Gynecology Baskent University School of Medicine Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21565"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.04.013"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1248"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2761"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.1001"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050870"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4157-9"},{"key":"e_1_2_8_9_1","first-page":"1363","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Driel WJ","year":"2018","journal-title":"N Engl J Med"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00091"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-019-0509-1"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2019.06.009"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000310"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902626"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0275"},{"key":"e_1_2_8_16_1","first-page":"4997","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for first relapse of ovarian cancer","volume":"35","author":"Classe JM","year":"2015","journal-title":"Anticancer Res"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2018.1518544"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2510-4"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-1873-2"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31820aaafd"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24603"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.09.007"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.05.032"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2018.1503346"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3442-3"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.12.033"},{"key":"e_1_2_8_28_1","first-page":"2025","article-title":"Ascites do not affect the rate of complete cytoreductive surgery and prognosis in patients with primary ovarian cancer with ascites treated with hyperthermic intraperitoneal chemotherapy","volume":"18","author":"Ba M","year":"2019","journal-title":"Oncol Lett"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041842"}],"container-title":["International Journal of Gynecology &amp; Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijgo.13410","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijgo.13410","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijgo.13410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T04:53:33Z","timestamp":1693544013000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1002\/ijgo.13410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1002\/ijgo.13410"],"URL":"https:\/\/doi.org\/10.1002\/ijgo.13410","archive":["Portico"],"relation":{},"ISSN":["0020-7292","1879-3479"],"issn-type":[{"value":"0020-7292","type":"print"},{"value":"1879-3479","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,28]]},"assertion":[{"value":"2020-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}